Researchers Identify Genetic Mechanism Behind Rare Blood Clotting in Johnson & Johnson and AstraZeneca COVID Vaccines
Key Insights
Scientists have identified the genetic mechanism behind vaccine-induced immune thrombotic thrombocytopenia (search) (VITT (search)), a rare but potentially fatal blood clotting (search) condition linked to adenovirus (search)-based COVID vaccines.
The study published in The New England Journal of Medicine found that VITT (search) occurs in individuals with specific DNA variants whose immune cells produce cross-reactive antibodies against both the adenovirus (search) and PF4 (search), a blood clotting (search) molecule.
All 100 VITT (search) patients studied had one of two specific genetic variants, but required an additional genetic mutation in immune cells to develop the dangerous cross-reactive antibodies.
Scientists have solved the mystery behind the rare but potentially fatal blood clotting (search) condition that led to the withdrawal of Johnson & Johnson and AstraZeneca COVID vaccines from the market. A new study published in The New England Journal of Medicine reveals that vaccine-induced immune thrombotic thrombocytopenia (search) (VITT (search)) results from a specific genetic predisposition combined with an immune response gone awry.
Genetic Basis of Rare Vaccine Complication
The research, led by Andreas Greinacher, a blood expert at the University of Greifswald in Germany, analyzed antibodies from 21 VITT (search) patients and found that the condition stems from cross-reactive antibodies that bind to both the adenovirus (search) vector and PF4 (search), a molecule that influences blood clotting (search). Crucially, the study identified that all 100 VITT patients surveyed possessed one of two specific DNA variants that predispose individuals to this dangerous immune reaction.
"This is a landmark finding in part because of how elegantly it explains the way a specific genetic trait, combined with a particular chance mutation in certain cells, creates VITT (search)," said Arnold Lining Ju, a biomedical engineer at the University of Sydney who studies blood clotting (search).
Scale of the Problem
The blood clotting (search) issue affected both major adenovirus (search)-based COVID vaccines. Out of nearly 19 million Johnson & Johnson doses administered in the United States during the first two years of the pandemic, at least 60 VITT (search) cases were identified, with nine proving fatal. The numbers were more substantial for AstraZeneca: 455 cases occurred among almost 50 million doses given in the United Kingdom, resulting in 81 deaths, while Germany reported at least 71 cases.
Mechanism of Action Revealed
The study demonstrates that VITT (search) occurs when individuals with specific genetic variants develop antibodies that mistakenly target both the adenovirus (search) vaccine component and the body's own PF4 (search) molecule. However, genetic predisposition alone is insufficient—the immune cells must also undergo an additional small genetic mutation to produce the dangerous cross-reactive antibodies.
This dual requirement explains why VITT (search) remained so rare despite millions of vaccine doses administered. The research represents the first concrete evidence of how people with particular DNA variants can develop self-sabotaging antibodies following vaccination.
Implications for Future Vaccine Development
The findings have significant implications for precision vaccinology and future pandemic preparedness. "Instead of abandoning an entire vaccine platform because of a rare problem, we can engineer around the specific issue, and that's the power of this kind of science," said Joann Arce of the Precision Vaccines Program at Boston Children's Hospital.
Researchers believe adenovirus-based vaccines (search) could be redesigned to exclude the protein region that triggers dangerous antibodies in VITT (search) patients. This approach would preserve the utility of adenovirus (search) platforms, which remain important for developing vaccines for diseases affecting low- and middle-income countries and can be scaled up quickly during future pandemics.
Clinical and Research Impact
While the discovery will primarily guide researchers rather than influence individual vaccination choices—since most people don't know their genetic predisposition to adverse events—it represents a crucial step forward in vaccine safety science. Jennifer Juno, a vaccine researcher at the University of Melbourne, notes that this work will help improve vaccine design, particularly in precision vaccinology where vaccines are tailored to individual traits.
The research also provides a foundation for understanding other rare vaccine-related adverse events, potentially explaining genetic predispositions to conditions like narcolepsy (search) following certain swine flu vaccines used in Europe.